STOCK TITAN

SOPHiA GENETICS (SOPH) CEO sells 8,500 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 Ordinary Shares in an open-market transaction at a weighted average price of $5.2354 per share. Following the sale, he directly holds 3,620,995 shares.

The sale was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The shares were sold in multiple trades at prices ranging from $5.13 to $5.42.

Positive

  • None.

Negative

  • None.
Insider Camblong Jurgi
Role Chief Executive Officer
Sold 8,500 shs ($45K)
Type Security Shares Price Value
Sale Ordinary Shares 8,500 $5.2354 $45K
Holdings After Transaction: Ordinary Shares — 3,620,995 shares (Direct, null)
Footnotes (1)
  1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.42, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 8,500 shares Open-market sale of Ordinary Shares
Weighted average sale price $5.2354 per share Average price for the 8,500 shares sold
Post-transaction holdings 3,620,995 shares Shares directly held after the sale
Price range of trades $5.13–$5.42 per share Range of individual transaction prices
Net shares sold 8,500 shares Net sell direction from transactionSummary
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Ordinary Shares financial
"security_title": "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Camblong Jurgi

(Last)(First)(Middle)
C/O SOPHIA GENETICS SA
LA PIECE 12

(Street)
ROLLE1180

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares06/10/2026S8,500(1)D$5.2354(2)3,620,995D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.42, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for Jurgi Camblong?

SOPHiA GENETICS reported that CEO Jurgi Camblong sold 8,500 Ordinary Shares. The transaction was an open-market sale executed under a Rule 10b5-1(c) trading plan, indicating it was pre-arranged rather than a spontaneous market decision.

At what price did the SOPHiA GENETICS (SOPH) CEO sell his shares?

The CEO’s shares were sold at a weighted average price of $5.2354 per share. Individual trades occurred in multiple transactions, with prices ranging from $5.13 to $5.42, according to the disclosed pricing footnote in the filing.

How many SOPHiA GENETICS (SOPH) shares does the CEO hold after the sale?

After selling 8,500 Ordinary Shares, CEO Jurgi Camblong directly holds 3,620,995 shares. This remaining position shows he retained the large majority of his holdings following the reported open-market sale on the transaction date.

Was the SOPHiA GENETICS (SOPH) CEO sale made under a Rule 10b5-1 plan?

Yes, the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans pre-schedule trades, helping separate routine portfolio management from timing based on short-term information.

What type of security did the SOPHiA GENETICS (SOPH) insider sell?

The reported transaction involved Ordinary Shares of SOPHiA GENETICS SA. It was classified as a non-derivative open-market sale, meaning the insider sold actual shares rather than exercising or converting derivative securities such as options or warrants.